Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study
Purpose. Evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis. Patients and Methods. 15 patients with Demodex blepharitis, defined as >10 collarettes on the upper lid, lid margin erythema, and Demodex density of ≥1.5 mites/lash on m...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2021/3862684 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524645264621568 |
|---|---|
| author | Roberto Gonzalez-Salinas Elizabeth Yeu Mark Holdbrook Stephanie N. Baba Juan Carlos Ceballos Martha Massaro-Corredor Claudia Corredor-Ortega Nallely Ramos-Betancourt Hugo Quiroz-Mercado |
| author_facet | Roberto Gonzalez-Salinas Elizabeth Yeu Mark Holdbrook Stephanie N. Baba Juan Carlos Ceballos Martha Massaro-Corredor Claudia Corredor-Ortega Nallely Ramos-Betancourt Hugo Quiroz-Mercado |
| author_sort | Roberto Gonzalez-Salinas |
| collection | DOAJ |
| description | Purpose. Evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis. Patients and Methods. 15 patients with Demodex blepharitis, defined as >10 collarettes on the upper lid, lid margin erythema, and Demodex density of ≥1.5 mites/lash on microscopy, were treated bid for 28 days with lotilaner ophthalmic solution, 0.25%. Contact lens wear, artificial eyelashes, and lid structural abnormalities were among the exclusion criteria. No other antibacterial, antiparasitic, or anti-inflammatory treatment or lid hygiene products were permitted. Patients were assessed on Days 7, 14, 28, 60, and 90. Outcome measures were changes in collarette grade and mite density on Day 28. Adverse events and changes in intraocular pressure (IOP), corrected distance visual acuity (CDVA), and slit-lamp biomicroscopy were assessed. Results. Mean collarette grade (upper lids) improved from 3.07 ± 0.21 to 0.79 ± 0.19 on Day 28; the change was statistically significant for both upper and lower lids from Day 14 on. Mean mite density per lash decreased from 2.28 ± 0.16 at baseline to 0.14 ± 0.05 at Day 28 p<0.0001. Mite eradication (0 mites) was documented in 57.1% of eyes. The effects were durable through Day 90. There were no adverse events and little to no change in CDVA or IOP. The drop was well tolerated, with no discontinuations due to ocular irritation. Conclusion. Topical lotilaner ophthalmic solution, 0.25% for 4 weeks, showed promising efficacy for the treatment of Demodex blepharitis. This novel treatment appears to be safe and well tolerated. Randomized controlled studies are needed to confirm the results. |
| format | Article |
| id | doaj-art-8965145fb5ad4b9fb41e89a0cf1a4937 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-8965145fb5ad4b9fb41e89a0cf1a49372025-02-03T05:47:40ZengWileyJournal of Ophthalmology2090-004X2090-00582021-01-01202110.1155/2021/38626843862684Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot StudyRoberto Gonzalez-Salinas0Elizabeth Yeu1Mark Holdbrook2Stephanie N. Baba3Juan Carlos Ceballos4Martha Massaro-Corredor5Claudia Corredor-Ortega6Nallely Ramos-Betancourt7Hugo Quiroz-Mercado8Asociación Para Evitar la Ceguera en México I.A.P., Mexico City, MexicoVirginia Eye Consultants, Norfolk, VA, USATarsus Pharmaceuticals, Inc., Irvine, CA, USATarsus Pharmaceuticals, Inc., Irvine, CA, USAAsociación Para Evitar la Ceguera en México I.A.P., Mexico City, MexicoAsociación Para Evitar la Ceguera en México I.A.P., Mexico City, MexicoAsociación Para Evitar la Ceguera en México I.A.P., Mexico City, MexicoAsociación Para Evitar la Ceguera en México I.A.P., Mexico City, MexicoAsociación Para Evitar la Ceguera en México I.A.P., Mexico City, MexicoPurpose. Evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis. Patients and Methods. 15 patients with Demodex blepharitis, defined as >10 collarettes on the upper lid, lid margin erythema, and Demodex density of ≥1.5 mites/lash on microscopy, were treated bid for 28 days with lotilaner ophthalmic solution, 0.25%. Contact lens wear, artificial eyelashes, and lid structural abnormalities were among the exclusion criteria. No other antibacterial, antiparasitic, or anti-inflammatory treatment or lid hygiene products were permitted. Patients were assessed on Days 7, 14, 28, 60, and 90. Outcome measures were changes in collarette grade and mite density on Day 28. Adverse events and changes in intraocular pressure (IOP), corrected distance visual acuity (CDVA), and slit-lamp biomicroscopy were assessed. Results. Mean collarette grade (upper lids) improved from 3.07 ± 0.21 to 0.79 ± 0.19 on Day 28; the change was statistically significant for both upper and lower lids from Day 14 on. Mean mite density per lash decreased from 2.28 ± 0.16 at baseline to 0.14 ± 0.05 at Day 28 p<0.0001. Mite eradication (0 mites) was documented in 57.1% of eyes. The effects were durable through Day 90. There were no adverse events and little to no change in CDVA or IOP. The drop was well tolerated, with no discontinuations due to ocular irritation. Conclusion. Topical lotilaner ophthalmic solution, 0.25% for 4 weeks, showed promising efficacy for the treatment of Demodex blepharitis. This novel treatment appears to be safe and well tolerated. Randomized controlled studies are needed to confirm the results.http://dx.doi.org/10.1155/2021/3862684 |
| spellingShingle | Roberto Gonzalez-Salinas Elizabeth Yeu Mark Holdbrook Stephanie N. Baba Juan Carlos Ceballos Martha Massaro-Corredor Claudia Corredor-Ortega Nallely Ramos-Betancourt Hugo Quiroz-Mercado Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study Journal of Ophthalmology |
| title | Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study |
| title_full | Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study |
| title_fullStr | Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study |
| title_full_unstemmed | Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study |
| title_short | Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study |
| title_sort | safety and efficacy of topical lotilaner ophthalmic solution 0 25 for the treatment of demodex blepharitis a pilot study |
| url | http://dx.doi.org/10.1155/2021/3862684 |
| work_keys_str_mv | AT robertogonzalezsalinas safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT elizabethyeu safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT markholdbrook safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT stephanienbaba safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT juancarlosceballos safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT marthamassarocorredor safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT claudiacorredorortega safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT nallelyramosbetancourt safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy AT hugoquirozmercado safetyandefficacyoftopicallotilanerophthalmicsolution025forthetreatmentofdemodexblepharitisapilotstudy |